Publication:
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.

dc.contributor.authorPlasencia-García, Beatriz Oda
dc.contributor.authorRodríguez-Menéndez, Gonzalo
dc.contributor.authorRico-Rangel, María Isabel
dc.contributor.authorRubio-García, Ana
dc.contributor.authorTorelló-Iserte, Jaime
dc.contributor.authorCrespo-Facorro, Benedicto
dc.date.accessioned2023-02-09T10:39:21Z
dc.date.available2023-02-09T10:39:21Z
dc.date.issued2021-01-07
dc.description.abstractManagement of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics should consider eventual drug-drug interactions OBJECTIVE: To systematically review evidence-based available on drug-drug interactions between COVID-19 treatments and antipsychotics. Three databases were consulted: Lexicomp® Drug Interactions, Micromedex® Solutions Drugs Interactions, and Liverpool© Drug Interaction Group for COVID-19 therapies. To acquire more information on QT prolongation and Torsade de Pointes (TdP), the CredibleMeds® QTDrugs List was searched. The authors made a recommendation agreed to by consensus. Additionally, a systematic review of drug-drug interactions between antipsychotics and COVID-19 treatment was conducted. The main interactions between COVID-19 drugs and antipsychotics are the risk of QT-prolongation and TdP, and cytochromes P450 interactions. Remdesivir, baricinitib, and anakinra can be used concomitantly with antipsychotics without risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib). Favipiravir only needs caution with chlorpromazine and quetiapine. Tocilizumab is rather safe to use in combination with antipsychotics. The most demanding COVID-19 treatments for coadministration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir because of the risk of QT prolongation and TdP and cytochromes interactions. The systematic review provides highly probable drug interaction between lopinavir/ritonavir plus quetiapine and ritonavir/indinavir plus risperidone. Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety.
dc.identifier.doi10.1007/s00213-020-05716-4
dc.identifier.essn1432-2072
dc.identifier.pmcPMC7788177
dc.identifier.pmid33410987
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788177/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s00213-020-05716-4.pdf
dc.identifier.urihttp://hdl.handle.net/10668/16935
dc.issue.number2
dc.journal.titlePsychopharmacology
dc.journal.titleabbreviationPsychopharmacology (Berl)
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number329-340
dc.pubmedtypeJournal Article
dc.pubmedtypeSystematic Review
dc.rights.accessRightsopen access
dc.subjectCOVID-19
dc.subjectDrug-drug interaction
dc.subjectPsychopharmacotherapy
dc.subjectSide effects
dc.subject.meshAntipsychotic Agents
dc.subject.meshAntiviral Agents
dc.subject.meshCytochrome P-450 Enzyme System
dc.subject.meshDrug Interactions
dc.subject.meshHumans
dc.subject.meshLong QT Syndrome
dc.subject.meshSARS-CoV-2
dc.subject.meshTorsades de Pointes
dc.subject.meshCOVID-19 Drug Treatment
dc.titleDrug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number238
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7788177.pdf
Size:
1.16 MB
Format:
Adobe Portable Document Format